Compound Libraries

- A unique collection of 3111 plant-sourced compounds; - All are in preclinical or clinical research phases with the most research potential; - Includes many popular natural products, such as Artemisinin, Ginsenoside, etc.; - Structurally diverse, medicinally active, and cell permeable; - Detailed compound information with structure, target, activity, IC50 value, and biological activity description; - NMR and HPLC/LCMS validated to ensure high purity and quality.

- Quantity: well-chosen 1246 compounds with unique structures targeting nervous system; - High bioactivity: All compounds with IC50 below 3.5 μM; - Covers 52 nervous system disease related targets with each compound having clear target; - Detailed information: each compound has information about activity testing method, providing reference for your experimental design; - A supplemental tool for nervous system disease drug development and target identification.

- A unique collection of 4940 anti-inflammation compounds effective for high throughput screening and high content screening. - Bioactivity and safety confirmed by clinical research and trials, some of which are FDA approved; - Detailed compound information with structure, target, activity, IC50 value, and biological activity description; - Structurally diverse, medicinally active, and cell permeable; - NMR and HPLC validated to ensure high purity and quality;

- A unique collection of 609 nonsteroidal anti-inflammatory related compounds can be used for HTS and HCS; - Contains common NSAIDs, such as aspirin, indomethacin, ibuprofen, Sulindac, Piroxicam, etc.； - Detailed compound information with structure, target, and biological activity description； - NMR and HPLC validated to ensure high purity and quality.

- A unique collection of 2300 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high throughput screening (HTS) and high content screening (HCS); - Targets include angiogenesis signaling, and related targets such as S1P, VEGFR, PDGF, etc.; - Includes approved drugs targeting angiogenesis, such as Sunitinib Malate, Lenalidomide, sorafenib, Erlotinib; drugs in clinical development with the most potential targeting angiogenesis, such as Vatalanib, Orantinib, 2-Methoxyestradiol (Panzem), Celecoxib; - Detailed compound information with structure, target, activity, IC50 value, and biological activity description; - Structurally diverse, medicinally active, and cell permeable; - NMR and HPLC validated to ensure high purity and quality;

- A unique collection of 131 cardiotoxicity inducing compounds for toxicological study; - Includes various compounds with different structures and mechanisms; - Detailed compound information with structure, target, activity, IC50 value, and biological activity description; - Structurally diverse, medicinally active, and cell permeable; - NMR and HPLC validated to ensure high purity and quality;

- A unique collection of 2684 fluorochemicals that can be used for high through-put screening (HTS) and high content screening (HCS); - Bioactivity and safety confirmed by pre-clinical research and clinical trials, and some of them are approved by FDA; - Detailed compound information with structure, target, activity, IC50 value, and biological activity description; - NMR and HPLC validated to ensure high purity and quality; - All compounds are in stock.

- A unique collection of 1544 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS); - Bioactivity and safety confirmed by pre-clinical research and clinical trials and most of them are approved for marketing by FDA, EMA, or NMPA; - Covers various major targets including CYP, FAAH, IDO, MAO, etc., in diabetes, obesity, hypertriglyceridemia, hypercholesterolemia, etc.; Effective tool for cell metabolism research; - Detailed compound information with structure, target, activity, IC50 value, and biological activity description; - Structurally diverse, medicinally active, and cell permeable; - NMR and HPLC validated to ensure high purity and quality;

- A unique collection of 950 promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine; - Targets include mitochondria related targets, such as ATPase, mitochondria-associated hexokinase, Bcl-2, NADP, etc. and inhibitors for the autophagy initiating factor, ULK1, also include other promising mitochondria-targeted compounds such as lonidamine, paclitaxel, etc; - Bioactivity and safety confirmed by pre-clinical research and clinical trials; - Detailed compound information with structure, target, activity, IC50 value, and biological activity description; - Structurally diverse, medicinally active, and cell permeable; - NMR and HPLC validated to ensure high purity and quality;